Alzheimer’s disease (AD) is a progressive neurodegenerative disease. AD patients suffer from slow deterioration of memory and cognitive functions, which may eventually lead to death. AD is the most common form of dementia and it is estimated that more than 6 million American are living with AD in 2019. The genetic causes are largely unknown in sporadic AD (sAD) while few genetic aberrations have been identified in familiar AD (fAD). However, no effective treatments have been developed to slow down or change the disease course.AcceGen has generated human induced pluripotent stem cells (hiPSCs) derived from a patient with familiar Alzheimer’s disease (fAD). These iPS cells are established from a single clone and expanded in feeder-free condition. All the cells provided by AcceGen are negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C. Recently, hiPSCs have been shown to serve as a versatile tool to investigate and model various diseases including AD and other neurodegenerative diseases. Therefore, our hiPSCs carrying fAD mutation (PSEN2 N141I) will meet the clients’ need to study the molecular basis of AD progression and further to develop potential therapeutic approaches.
